Table 1 Study population characteristics (n = 15)
Age, mean (SD) | 47.6 (10.7) |
Race, n (%) | |
White | 14 (93) |
Black or African American | 1 (7) |
Sex, n (%) | |
female | 10 (67) |
male | 5 (33) |
Presence of ANA, n (%) | 14 (93) |
ANA Patterna, n (%) | |
speckled | 10 (67) |
homogeneous | 4 (27) |
nucleolar | 1 (7) |
Scl-70 | 4 (27) |
RNP | 0 |
SSA/SSB | 0 |
dsDNA | 0 |
WBC (per μL), mean (SD) | 7907 (2077) |
ESRb, mean (SD), mm/h | 15.4 (8.8) |
Medication use, n (%) | |
Antifibrotic agentc | |
mycophenolate mofetil | 12 (80) |
mycophenolic acid | 2 (13) |
methotrexate | 1 (7) |
cyclophosphamide | 1 (7) |
prednisone | |
(none) | 9 (60) |
5 mg/d | 3 (33) |
10 mg/d | 1 (7) |
PPI | 8 (53) |
CCB | 4 (27) |
ACEi | 5 (33) |
ARB | 0 |
statin | 2 (13) |
ASA | 5 (34) |
NSAID | 1 (7) |
Clinical symptoms, n (%) | |
ILD | 4 (27) |
SIBO | 1 (7) |
GERD | 9 (60) |
Hypothyroidism | 2 (13) |
Raynaud’s | 15 (100) |
DU | 4 (27) |
GAVE | 1 (7) |
Esophageal dysmotility | 5 (33) |
Pericardial effusion | 1 (7) |
SRC | 1 (7) |
HTN | 1 (7) |
Arthritis | 2 (13) |
Sicca | 1 (7) |
Calcinosis | 1 (7) |
Intestinal Pseudobstruction | 1 (7) |
Disease duration months(SD) | |
Raynaud’s | 37 ± 40 |
Skin sclerosis | 19 ± 15 |